U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408869) titled 'A Phase 1 Study of Cizutamig in IgE Mediated Diseases' on Dec. 23, 2025.
Brief Summary: The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
IgE-Mediated Hypersensitivity
IgE Mediated Food Allergy
IgE-Mediated Cow Milk Allergy
Intervention:
BIOLOGICAL: Cizutamig
cizutamig will be dosed SC according to the assigned cohort
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Candid Therapeutics
Disclaimer: Curated by HT Syndication....